ADAM-17: a novel therapeutic target for triple negative breast cancer.
AuthorsMcGowan, P M
Madden, S F
Maguire, A A
McDermott, E W
Duffy, M J
AffiliationDepartment of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin, Ireland. email@example.com
Local subject classificationCELL BIOLOGY
Cell Line, Tumor
Molecular Targeted Therapy
Receptor, Epidermal Growth Factor
Transforming Growth Factor alpha
MetadataShow full item record
CitationMcGowan PM et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann. Oncol. 2013, 24 (2):362-9
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
AbstractValidated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.